REPURPOSE: PHASE II STUDY ASSESSING THE EFFICACY OF EFAVIRENZ, AN APPROVED HIV DRUG REPURPOSED AS AN ANTI-CANCER AGENT, IN PATIENTS WITH PLATINUM RESISTANT OVARIAN CANCERJanine Lombard, Nikola A. Bowden, Hiren Mandaliya et al.|International Journal of Gynecological Cancer|2025Cited by 0